Post Gastrectomy State
Conditions
Brief summary
Recent study showed that SIBO is common among postgastrectomy patients and It appears to be associated with postprandial intestinal symptoms and might aggravate late hypoglycemia. SIBO could be a new therapeutic target for managing intestinal symptoms in postgastrectomy patients.The purpose of this study is to determine whether antiboitic (metronidazole) is effective in patients with postgasrectomy syndrome
Interventions
DRUGmetronidazole
DRUGPlacebo
Sponsors
The Catholic University of Korea
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* age between 18 and 70 * gastrectomy for early gastric cancer with complete resection * no reccurrence after follow up more than 6 months * identified small bowel bacterial overgrowth by hydrogen breath test * symptoms of postgastrectomy syndrome
Exclusion criteria
* hypersensive to metronidazole * systemic chemotherapy history * other organic gastrointestinal disease (inflammatory bowel disease, carcinoid syndrome, amyloidosis, intestinal obstruction) * other gastrointestinal operation history except appendectomy, cholecystectomy) * recent colonoscopic examination (within 30 days) * uncontrolled psychopathy * drug or alcohol abuser * pregnant or breast feeding woman * recent history of antibiotics treatment (within 90 days) * recent history of PPI or H2 blocker treatment (within 30 dyas) * recent history of probiotics treatment (within 30 dyas) * recent history of prokinetics or antispasmotic treatment (within 15 days) * severe systemic illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient's Global Assessment of abdominal symptom | 4 week |
Outcome results
None listed